887 related articles for article (PubMed ID: 16862165)
21. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
[TBL] [Abstract][Full Text] [Related]
22. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease.
Chan GW; Gorgun G; Miller KB; Foss FM
Biol Blood Marrow Transplant; 2003 Mar; 9(3):170-6. PubMed ID: 12652467
[TBL] [Abstract][Full Text] [Related]
23. Mixed chimera converted into full donor chimera with powerful graft-versus-leukemia effects but no graft-versus-host disease after non T cell-depleted HLA-mismatched peripheral blood stem cell transplantation.
Wu BY; Guo KY; Song CY; Yang ; Li D
Bone Marrow Transplant; 2000 Sep; 26(6):691-3. PubMed ID: 11035376
[TBL] [Abstract][Full Text] [Related]
24. Prevention and treatment of graft-versus-host disease by down-regulation of anti-host reactivity with veto cells of host origin.
Weiss L; Slavin S
Bone Marrow Transplant; 1999 Jun; 23(11):1139-43. PubMed ID: 10382953
[TBL] [Abstract][Full Text] [Related]
25. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
Weiss L; Reich S; Slavin S
Cytokines Cell Mol Ther; 1999 Sep; 5(3):145-52. PubMed ID: 10641572
[TBL] [Abstract][Full Text] [Related]
26. Complete allogeneic hematopoietic chimerism achieved by in utero hematopoietic cell transplantation and cotransplantation of LLME-treated, MHC-sensitized donor lymphocytes.
Hayashi S; Hsieh M; Peranteau WH; Ashizuka S; Flake AW
Exp Hematol; 2004 Mar; 32(3):290-9. PubMed ID: 15003315
[TBL] [Abstract][Full Text] [Related]
27. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
[TBL] [Abstract][Full Text] [Related]
28. An absence of CCR5 on donor cells results in acceleration of acute graft-vs-host disease.
Welniak LA; Wang Z; Sun K; Kuziel W; Anver MR; Blazar BR; Murphy WJ
Exp Hematol; 2004 Mar; 32(3):318-24. PubMed ID: 15003318
[TBL] [Abstract][Full Text] [Related]
29. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.
Taniguchi Y; Yoshihara S; Hoshida Y; Inoue T; Fujioka T; Ikegame K; Kawakami M; Masuda T; Aozasa K; Kawase I; Ogawa H
Exp Hematol; 2008 Sep; 36(9):1216-25. PubMed ID: 18599183
[TBL] [Abstract][Full Text] [Related]
30. [Role of TJU103 in prevention of graft-versus-host disease after allogeneic stem cell transplantation in mice].
Wang SB; Guo KY; Hu DM; Yin B
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jun; 26(6):810-3. PubMed ID: 16793606
[TBL] [Abstract][Full Text] [Related]
31. Multidonor bone marrow transplantation improves donor engraftment and increases the graft versus tumor effect while decreasing graft-versus-host disease.
Zhanna Y; Ester H; Lola W; Offer G; Shimon S; Shapira MY
Transpl Int; 2011 Feb; 24(2):194-200. PubMed ID: 20854413
[TBL] [Abstract][Full Text] [Related]
32. Effect of cyclosporine A and methylprednisolone on the graft-versus-leukemia effects across major histocompatibility barriers in mice following allogeneic bone marrow transplantation.
Weiss L; Reich S; Slavin S
Bone Marrow Transplant; 1990 Oct; 6(4):229-33. PubMed ID: 2085696
[TBL] [Abstract][Full Text] [Related]
33. Rapid immune reconstitution after a reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric refractory haematological malignancies.
Chen X; Hale GA; Barfield R; Benaim E; Leung WH; Knowles J; Horwitz EM; Woodard P; Kasow K; Yusuf U; Behm FG; Hayden RT; Shurtleff SA; Turner V; Srivastava DK; Handgretinger R
Br J Haematol; 2006 Nov; 135(4):524-32. PubMed ID: 17010105
[TBL] [Abstract][Full Text] [Related]
34. [Second transplant from the same donor without conditioning for bone marrow aplasia after non-myeloablative hematopoietic stem cell transplantation for chronic myeloid leukemia].
Ishikawa I; Miyamura K; Yamada M; Sasaki O; Harigae H; Kameoka J; Meguro K; Sasaki T
Rinsho Ketsueki; 2005 Dec; 46(12):1288-92. PubMed ID: 16447801
[TBL] [Abstract][Full Text] [Related]
35. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
[TBL] [Abstract][Full Text] [Related]
36. Partial CD8+ T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease.
Ho VT; Kim HT; Li S; Hochberg EP; Cutler C; Lee SJ; Fisher DC; Milford E; Kao G; Daley H; Levin J; Ng A; Mauch P; Alyea EP; Antin JH; Soiffer RJ
Bone Marrow Transplant; 2004 Dec; 34(11):987-94. PubMed ID: 15489873
[TBL] [Abstract][Full Text] [Related]
37. Effect of KRN7000 on induced graft-vs-host disease.
Morecki S; Panigrahi S; Pizov G; Yacovlev E; Gelfand Y; Eizik O; Slavin S
Exp Hematol; 2004 Jul; 32(7):630-7. PubMed ID: 15246159
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy by allogeneic stem cell transplantation.
Ringdén O
Adv Cancer Res; 2007; 97():25-60. PubMed ID: 17419940
[TBL] [Abstract][Full Text] [Related]
39. Hematopoietic stem cell recipients do not develop post-transplantation immune tolerance to antigens present on minimal residual disease.
Natzke AM; Shaw JL; McKeller MR; Emo KL; Mullen CA
Biol Blood Marrow Transplant; 2007 Jan; 13(1):34-45. PubMed ID: 17222751
[TBL] [Abstract][Full Text] [Related]
40. Experimental and clinical approaches for optimization of the graft-versus-leukemia effect.
Sprangers B; Van Wijmeersch B; Fevery S; Waer M; Billiau AD
Nat Clin Pract Oncol; 2007 Jul; 4(7):404-14. PubMed ID: 17597705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
